• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在两名患有免疫性血小板减少症且有生活方式限制的儿童临床出血发作前积极使用艾曲泊帕。

Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions.

作者信息

Bergmann Shayla

机构信息

Department of Pediatric Hematology/Oncology Medical University of South Carolina 135 Rutledge Avenue MSC 558 Charleston 29425 South Carolina.

出版信息

Clin Case Rep. 2017 Sep 1;5(10):1660-1663. doi: 10.1002/ccr3.1086. eCollection 2017 Oct.

DOI:10.1002/ccr3.1086
PMID:29026567
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5628223/
Abstract

Children with immune thrombocytopenia (ITP) are often managed using a watch-and-wait approach to avoid conventional treatment that may be poorly tolerated. However, in some patients, this approach may lead to lifestyle restrictions due to risk of injury-related bleeding. Eltrombopag is a well-tolerated new option that may help these children.

摘要

患有免疫性血小板减少症（ITP）的儿童通常采用观察等待的方法进行治疗，以避免使用耐受性可能较差的传统治疗方法。然而，在一些患者中，由于存在与损伤相关的出血风险，这种方法可能会导致生活方式受到限制。艾曲泊帕是一种耐受性良好的新选择，可能对这些儿童有所帮助。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d625/5628223/7527917ba36e/CCR3-5-1660-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d625/5628223/7527917ba36e/CCR3-5-1660-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d625/5628223/7527917ba36e/CCR3-5-1660-g001.jpg

相似文献

1
Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions.在两名患有免疫性血小板减少症且有生活方式限制的儿童临床出血发作前积极使用艾曲泊帕。
Clin Case Rep. 2017 Sep 1;5(10):1660-1663. doi: 10.1002/ccr3.1086. eCollection 2017 Oct.
2
Use of Eltrombopag in Children With Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).艾曲泊帕在儿童慢性免疫性血小板减少症（ITP）中的应用：意大利儿科血液学和肿瘤学协会（AIEOP）的真实回顾性多中心经验
Front Med (Lausanne). 2020 Feb 28;7:66. doi: 10.3389/fmed.2020.00066. eCollection 2020.
3
Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.聚焦于难治性慢性原发性免疫性血小板减少症的艾曲泊帕治疗。
BioDrugs. 2011 Dec 1;25(6):401-4. doi: 10.2165/11207620-000000000-00000.
4
A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.艾曲泊帕用于儿童慢性免疫性血小板减少症的实用指南。
Pediatr Hematol Oncol. 2017 Mar;34(2):73-89. doi: 10.1080/08880018.2017.1313918. Epub 2017 May 24.
5
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.艾曲泊帕在临床实践中用于原发性慢性免疫性血小板减少症的安全性和有效性。
Eur J Haematol. 2016 Sep;97(3):297-302. doi: 10.1111/ejh.12725. Epub 2016 Jan 27.
6
The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.在美国，艾曲波帕治疗免疫性血小板减少症的成本效益分析。
Clin Ther. 2020 May;42(5):860-872.e8. doi: 10.1016/j.clinthera.2020.02.020. Epub 2020 Mar 18.
7
Eltrombopag for use in children with immune thrombocytopenia.艾曲波帕在儿童免疫性血小板减少症中的应用。
Blood Adv. 2018 Feb 27;2(4):454-461. doi: 10.1182/bloodadvances.2017010660.
8
Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.艾曲泊帕：新型非肽类血小板生成素受体激动剂在免疫性血小板减少症治疗中的研究进展。
Ann Hematol. 2010 Jul;89 Suppl 1:67-74. doi: 10.1007/s00277-010-0953-x. Epub 2010 Apr 20.
9
Advances in Diagnosis and Treatments for Immune Thrombocytopenia.免疫性血小板减少症的诊断与治疗进展
Clin Med Insights Blood Disord. 2016 Jul 17;9:15-22. doi: 10.4137/CMBD.S39643. eCollection 2016.
10
Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.在艾曲泊帕前瞻性临床研究中，对24例慢性免疫性血小板减少症患者进行的牙科手术。
Platelets. 2015;26(1):93-6. doi: 10.3109/09537104.2013.870333. Epub 2014 Jan 16.

引用本文的文献

1
Use of Eltrombopag in Children With Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).艾曲泊帕在儿童慢性免疫性血小板减少症（ITP）中的应用：意大利儿科血液学和肿瘤学协会（AIEOP）的真实回顾性多中心经验
Front Med (Lausanne). 2020 Feb 28;7:66. doi: 10.3389/fmed.2020.00066. eCollection 2020.

本文引用的文献

1
How I treat refractory immune thrombocytopenia.我如何治疗难治性免疫性血小板减少症。
Blood. 2016 Sep 22;128(12):1547-54. doi: 10.1182/blood-2016-03-603365. Epub 2016 Apr 6.
2
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.利妥昔单抗二线治疗成人免疫性血小板减少症（RITP 试验）：一项多中心、随机、双盲、安慰剂对照试验。
Lancet. 2015 Apr 25;385(9978):1653-61. doi: 10.1016/S0140-6736(14)61495-1. Epub 2015 Feb 5.
3
Clinical practice: immune thrombocytopenia in paediatrics.
临床实践：儿童免疫性血小板减少症
Eur J Pediatr. 2014 Feb;173(2):163-72. doi: 10.1007/s00431-013-2254-6. Epub 2014 Jan 5.
4
Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up.8149 名无癌症美国退伍军人行脾切除术后的长期风险：一项长达 27 年随访的队列研究。
Haematologica. 2014 Feb;99(2):392-8. doi: 10.3324/haematol.2013.092460. Epub 2013 Sep 20.
5
Positioning new treatments in the management of immune thrombocytopenia.定位新疗法在免疫性血小板减少症管理中的作用。
Pediatr Blood Cancer. 2013;60 Suppl 1(Suppl 1):S19-22. doi: 10.1002/pbc.24341. Epub 2012 Oct 25.
6
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.美国血液学会 2011 年免疫性血小板减少症循证实践指南。
Blood. 2011 Apr 21;117(16):4190-207. doi: 10.1182/blood-2010-08-302984. Epub 2011 Feb 16.
7
The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports.儿童和成人免疫性血小板减少性紫癜的发病率：已发表报告的批判性回顾。
Am J Hematol. 2010 Mar;85(3):174-80. doi: 10.1002/ajh.21616.
8
International consensus report on the investigation and management of primary immune thrombocytopenia.国际原发性免疫性血小板减少症诊治共识报告
Blood. 2010 Jan 14;115(2):168-86. doi: 10.1182/blood-2009-06-225565. Epub 2009 Oct 21.
9
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.成人及儿童免疫性血小板减少性紫癜术语、定义及疗效标准的标准化：国际工作组报告
Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.
10
Idiopathic thrombocytopenic purpura: beyond consensus.特发性血小板减少性紫癜：超越共识
Curr Opin Pediatr. 2000 Feb;12(1):4-9. doi: 10.1097/00008480-200002000-00002.